Anti-CCR8 monoclonal antibodies and uses thereof
Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C—C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).
1. A monoclonal antibody or antigen-binding fragment thereof having binding specificity to a human chemokine (C—C motif) receptor 8 (CCR8) protein, wherein the antibody or fragment thereof each comprises a heavy chain variable region comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3 and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, and wherein:
the CDRH1 comprises the amino acid sequence of SEQ ID NO: 35,
the CDRH2 comprises the amino acid sequence of SEQ ID NO: 36,
the CDRH3 comprises the amino acid sequence of SEQ ID NO: 37,
the CDRL1 comprises the amino acid sequence of SEQ ID NO: 25,
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 26, and
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 27.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 38-40, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 32-34 and 41-43.
3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:40, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:42.
4. The antibody or antigen-binding fragment thereof of claim 1 , which is humanized.
5. The antibody or antigen-binding fragment of claim 1 , which is capable of mediating antibody-dependent cellular cytotoxicity (ADCC).
6. The antibody or antigen-binding fragment of claim 5 , which is fucosylated.
7. A composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.
8. The composition of claim 7 , further comprising a second antibody having specificity to a tumor antigen.
9. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antigen-binding fragment is F(ab′) 2 , Fab′, Fab, Fv, or scFv.